申请人:Merck Sharp & Dohme Corp.
公开号:US20150111866A1
公开(公告)日:2015-04-23
Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol and reducing LDL-cholesterol in human patients and for treating or preventing atherosclerosis.
具有I式结构的化合物,包括化合物的药学上可接受的盐,是CETP抑制剂,可用于提高人类患者的HDL胆固醇和降低LDL胆固醇,以及用于治疗或预防动脉粥样硬化。